PT1730303E - Mutações do gene pik3ca em cancros humanos - Google Patents
Mutações do gene pik3ca em cancros humanos Download PDFInfo
- Publication number
- PT1730303E PT1730303E PT57232779T PT05723277T PT1730303E PT 1730303 E PT1730303 E PT 1730303E PT 57232779 T PT57232779 T PT 57232779T PT 05723277 T PT05723277 T PT 05723277T PT 1730303 E PT1730303 E PT 1730303E
- Authority
- PT
- Portugal
- Prior art keywords
- dna
- homo sapiens
- mutation
- pik3ca
- synonymous
- Prior art date
Links
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 467
- 230000035772 mutation Effects 0.000 title claims abstract description 87
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 45
- 108090000623 proteins and genes Proteins 0.000 title abstract description 28
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims abstract description 54
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims description 38
- 108091026890 Coding region Proteins 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 10
- 102200085641 rs121913273 Human genes 0.000 claims description 8
- 102200085789 rs121913279 Human genes 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 210000000481 breast Anatomy 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 6
- 102200085790 rs121913281 Human genes 0.000 claims description 6
- 102200085792 rs121913286 Human genes 0.000 claims description 6
- 102200085697 rs772110575 Human genes 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 5
- 102200085639 rs104886003 Human genes 0.000 claims description 5
- 102200085622 rs121913272 Human genes 0.000 claims description 5
- 230000000392 somatic effect Effects 0.000 claims description 5
- 102200085634 rs1057519927 Human genes 0.000 claims description 4
- 102200085644 rs1057519930 Human genes 0.000 claims description 4
- 102200085782 rs121913277 Human genes 0.000 claims description 4
- 102200085788 rs121913279 Human genes 0.000 claims description 4
- 102200085787 rs121913283 Human genes 0.000 claims description 4
- 102220197892 rs121913284 Human genes 0.000 claims description 4
- 102200085703 rs121913287 Human genes 0.000 claims description 4
- 102200085770 rs397517202 Human genes 0.000 claims description 4
- 102200085646 rs587777790 Human genes 0.000 claims description 4
- 102200072143 rs61748441 Human genes 0.000 claims description 4
- 102200145422 rs869312749 Human genes 0.000 claims description 4
- 102220643127 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform_T1025N_mutation Human genes 0.000 claims description 3
- 102220011138 c.370C>A Human genes 0.000 claims description 3
- 230000001613 neoplastic effect Effects 0.000 claims description 3
- 102200085623 rs1057519925 Human genes 0.000 claims description 3
- 102220198237 rs1057519927 Human genes 0.000 claims description 3
- 102200085637 rs121913274 Human genes 0.000 claims description 3
- 102220084639 rs121913275 Human genes 0.000 claims description 3
- 102220197893 rs121913282 Human genes 0.000 claims description 3
- 102200085793 rs397517201 Human genes 0.000 claims description 3
- 102220198258 rs749415085 Human genes 0.000 claims description 3
- 102220176862 rs886054490 Human genes 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 210000005013 brain tissue Anatomy 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 210000003608 fece Anatomy 0.000 claims description 2
- 210000002445 nipple Anatomy 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 102200156860 rs387906985 Human genes 0.000 claims 1
- 102220025838 rs74953290 Human genes 0.000 claims 1
- 102220044719 rs79597821 Human genes 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 abstract description 20
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 10
- 102000020233 phosphotransferase Human genes 0.000 abstract description 10
- 108700020796 Oncogene Proteins 0.000 abstract description 6
- 210000001072 colon Anatomy 0.000 abstract description 6
- 102000043276 Oncogene Human genes 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 3
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 486
- 150000001875 compounds Chemical class 0.000 description 21
- 239000003999 initiator Substances 0.000 description 21
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 13
- 108700024394 Exon Proteins 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 208000005017 glioblastoma Diseases 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 description 6
- -1 Helicoidal domain Proteins 0.000 description 6
- 101000619536 Homo sapiens DNA-dependent protein kinase catalytic subunit Proteins 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 208000003200 Adenoma Diseases 0.000 description 5
- 208000000172 Medulloblastoma Diseases 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 4
- 102100029938 Serine/threonine-protein kinase SMG1 Human genes 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 101150035983 str1 gene Proteins 0.000 description 4
- 206010069754 Acquired gene mutation Diseases 0.000 description 3
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 101000904787 Homo sapiens Serine/threonine-protein kinase ATR Proteins 0.000 description 3
- 101000864057 Homo sapiens Serine/threonine-protein kinase SMG1 Proteins 0.000 description 3
- 101000623857 Homo sapiens Serine/threonine-protein kinase mTOR Proteins 0.000 description 3
- 101150063858 Pik3ca gene Proteins 0.000 description 3
- 102100023921 Serine/threonine-protein kinase ATR Human genes 0.000 description 3
- 102100032762 Transformation/transcription domain-associated protein Human genes 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000037439 somatic mutation Effects 0.000 description 3
- FKBFDTRILNZGAI-IMJSIDKUSA-N Asp-Cys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O FKBFDTRILNZGAI-IMJSIDKUSA-N 0.000 description 2
- ZARXTZFGQZBYFO-JQWIXIFHSA-N Asp-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(O)=O)N)C(O)=O)=CNC2=C1 ZARXTZFGQZBYFO-JQWIXIFHSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 description 2
- 101000595741 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
- 101000595467 Homo sapiens T-complex protein 1 subunit gamma Proteins 0.000 description 2
- 101000796673 Homo sapiens Transformation/transcription domain-associated protein Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 102100025063 Phosphatidylinositol 3-kinase C2 domain-containing subunit gamma Human genes 0.000 description 2
- 102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 description 2
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 description 2
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 2
- 102100020824 Serine-protein kinase ATM Human genes 0.000 description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
- 229910008045 Si-Si Inorganic materials 0.000 description 2
- 229910006411 Si—Si Inorganic materials 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 102200042533 rs121909612 Human genes 0.000 description 2
- 102220198044 rs121913285 Human genes 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 101710133359 Agglutinin receptor Proteins 0.000 description 1
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
- SIFXMYAHXJGAFC-WDSKDSINSA-N Arg-Asp Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O SIFXMYAHXJGAFC-WDSKDSINSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 102000002110 C2 domains Human genes 0.000 description 1
- 108050009459 C2 domains Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- NXTYATMDWQYLGJ-BQBZGAKWSA-N Cys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CS NXTYATMDWQYLGJ-BQBZGAKWSA-N 0.000 description 1
- WXOFKRKAHJQKLT-BQBZGAKWSA-N Cys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CS WXOFKRKAHJQKLT-BQBZGAKWSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 101100520033 Dictyostelium discoideum pikC gene Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 1
- JZDHUJAFXGNDSB-WHFBIAKZSA-N Glu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O JZDHUJAFXGNDSB-WHFBIAKZSA-N 0.000 description 1
- UQHGAYSULGRWRG-WHFBIAKZSA-N Glu-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(O)=O UQHGAYSULGRWRG-WHFBIAKZSA-N 0.000 description 1
- MFBYPDKTAJXHNI-VKHMYHEASA-N Gly-Cys Chemical compound [NH3+]CC(=O)N[C@@H](CS)C([O-])=O MFBYPDKTAJXHNI-VKHMYHEASA-N 0.000 description 1
- PFMUCCYYAAFKTH-YFKPBYRVSA-N Gly-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)CN PFMUCCYYAAFKTH-YFKPBYRVSA-N 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 1
- 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 1
- 101100352301 Homo sapiens PIK3CD gene Proteins 0.000 description 1
- 101000721646 Homo sapiens Phosphatidylinositol 3-kinase C2 domain-containing subunit gamma Proteins 0.000 description 1
- 101000595746 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 description 1
- 101000595751 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 description 1
- 101000721645 Homo sapiens Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- YOTNPRLPIPHQSB-XUXIUFHCSA-N Ile-Arg-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N YOTNPRLPIPHQSB-XUXIUFHCSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- MLTRLIITQPXHBJ-BQBZGAKWSA-N Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O MLTRLIITQPXHBJ-BQBZGAKWSA-N 0.000 description 1
- HIZYETOZLYFUFF-BQBZGAKWSA-N Leu-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O HIZYETOZLYFUFF-BQBZGAKWSA-N 0.000 description 1
- OTXBNHIUIHNGAO-UWVGGRQHSA-N Leu-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN OTXBNHIUIHNGAO-UWVGGRQHSA-N 0.000 description 1
- MYTOTTSMVMWVJN-STQMWFEESA-N Lys-Tyr Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 MYTOTTSMVMWVJN-STQMWFEESA-N 0.000 description 1
- IEIHKHYMBIYQTH-YESZJQIVSA-N Lys-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CCCCN)N)C(=O)O IEIHKHYMBIYQTH-YESZJQIVSA-N 0.000 description 1
- 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 1
- 101150097381 Mtor gene Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 101150026284 PIK3CD gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 101710152977 Phosphatidylinositol 3-kinase C2 domain-containing subunit gamma Proteins 0.000 description 1
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 description 1
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 description 1
- 102100025059 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta Human genes 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 101100008569 Rattus norvegicus Cst4 gene Proteins 0.000 description 1
- 240000001329 Salvia pomifera Species 0.000 description 1
- 201000006783 Seckel syndrome Diseases 0.000 description 1
- 201000000072 Seckel syndrome 1 Diseases 0.000 description 1
- IFPBAGJBHSNYPR-ZKWXMUAHSA-N Ser-Ile-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O IFPBAGJBHSNYPR-ZKWXMUAHSA-N 0.000 description 1
- 241000699284 Sergia Species 0.000 description 1
- 101710142052 Serine/threonine-protein kinase mTOR Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 101710164277 Tartrate-resistant acid phosphatase type 5 Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000013489 benign neoplasm of large intestine Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 1
- 229940125695 gastrointestinal agent Drugs 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 102000057995 human PIK3CA Human genes 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 102220094315 rs876659785 Human genes 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54888604P | 2004-03-02 | 2004-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1730303E true PT1730303E (pt) | 2013-10-31 |
Family
ID=35056655
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT57232779T PT1730303E (pt) | 2004-03-02 | 2005-02-18 | Mutações do gene pik3ca em cancros humanos |
| PT17197306T PT3296407T (pt) | 2004-03-02 | 2005-02-18 | Mutações do gene pik3ca em cancros humanos |
| PT191756063T PT3556866T (pt) | 2004-03-02 | 2005-02-18 | Mutações do gene de pik3ca em cancros humanos |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT17197306T PT3296407T (pt) | 2004-03-02 | 2005-02-18 | Mutações do gene pik3ca em cancros humanos |
| PT191756063T PT3556866T (pt) | 2004-03-02 | 2005-02-18 | Mutações do gene de pik3ca em cancros humanos |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US8026053B2 (https=) |
| EP (5) | EP2497836B1 (https=) |
| JP (10) | JP2007530017A (https=) |
| AU (2) | AU2005227148B2 (https=) |
| CA (1) | CA2560696C (https=) |
| CY (1) | CY1121975T1 (https=) |
| DK (3) | DK3556866T3 (https=) |
| ES (5) | ES2437590T3 (https=) |
| HU (1) | HUE045690T2 (https=) |
| LT (1) | LT3296407T (https=) |
| PL (2) | PL3296407T3 (https=) |
| PT (3) | PT1730303E (https=) |
| SI (2) | SI3296407T1 (https=) |
| WO (1) | WO2005091849A2 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007530017A (ja) | 2004-03-02 | 2007-11-01 | ザ ジョンズ ホプキンス ユニバーシティ | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
| EP1849877A1 (en) * | 2006-04-24 | 2007-10-31 | Erasmus University Medical Center Rotterdam | Replicative history of T-and B-cell subsets |
| WO2008109375A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof |
| GB2453173A (en) * | 2007-09-28 | 2009-04-01 | Dxs Ltd | Polynucleotide primers |
| KR20100105648A (ko) | 2007-12-03 | 2010-09-29 | 엔즌 파마슈티칼스, 인코포레이티드 | Ｐｉｋ３ｃａ 발현 조절용 ｒｎａ 길항제 화합물 |
| WO2009152346A2 (en) * | 2008-06-11 | 2009-12-17 | Intradigm Corporation | Compositions comprising phosphoinositide 3-kinase sirna and methods of use thereof |
| CN101445832B (zh) * | 2008-12-23 | 2011-09-14 | 广州益善生物技术有限公司 | Pik3ca基因突变的检测探针、液相芯片及其检测方法 |
| EP2553463B1 (en) | 2010-03-26 | 2017-05-03 | Hongzhi Zou | Methods and materials for detecting colorectal neoplasm |
| AU2011329180A1 (en) * | 2010-11-15 | 2013-05-02 | Enzon Pharmaceuticals, Inc. | Methods of treating cancers with HER3 and PIK3CA antisense oligonucleotides |
| JP2013545756A (ja) * | 2010-11-16 | 2013-12-26 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド | 投与および治療方法 |
| WO2012106175A1 (en) | 2011-02-02 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Trrap and grin2a mutations and use thereof for the diagnosis and treatment of melanoma |
| US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
| ES2986436T3 (es) | 2011-04-15 | 2024-11-11 | Univ Johns Hopkins | Sistema de secuenciación segura |
| US20140298493A1 (en) * | 2011-07-28 | 2014-10-02 | Somasekar Seshagiri | PIK3CA H1047R Knock-In Non-Human Animal Breast Cancer Model |
| US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
| WO2013177386A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Biotherapeutics Inc. | Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy |
| CN102816839A (zh) * | 2012-07-06 | 2012-12-12 | 杭州艾迪康医学检验中心有限公司 | 用于检测结直肠癌pik3ca基因热点突变位点的试剂盒 |
| ES2886507T5 (es) | 2012-10-29 | 2024-11-15 | Univ Johns Hopkins | Prueba de Papanicolaou para cánceres de ovario y de endometrio |
| EP2971075B1 (en) * | 2013-03-13 | 2018-08-15 | Roche Diagnostics GmbH | Methods and compositions for detecting mutations in the human pi3kca (pik3ca) gene |
| CA2902916C (en) | 2013-03-14 | 2018-08-28 | Mayo Foundation For Medical Education And Research | Detecting neoplasm |
| KR101501826B1 (ko) * | 2013-04-05 | 2015-03-13 | 연세대학교 산학협력단 | 위암에 대한 예후 예측 모형의 제조방법 |
| EP3027654B1 (en) * | 2013-07-30 | 2019-09-25 | Blueprint Medicines Corporation | Pik3c2g fusions |
| CN120700143A (zh) | 2014-03-31 | 2025-09-26 | 梅奥医学教育和研究基金会 | 检测结直肠赘生物 |
| DK3198026T3 (da) * | 2014-08-07 | 2020-01-20 | Pharmassist Ltd | Fremgangsmåde til bestemmelse af pik3ca-mutationsstatus i en prøve |
| US12391985B2 (en) | 2014-08-07 | 2025-08-19 | Pharmassist Ltd | Method of determining PIK3CA mutational status in a sample |
| US10184154B2 (en) | 2014-09-26 | 2019-01-22 | Mayo Foundation For Medical Education And Research | Detecting cholangiocarcinoma |
| CN104531854B (zh) * | 2014-11-10 | 2017-01-18 | 中国人民解放军第三〇七医院 | 检测西妥昔单抗治疗转移性结直肠癌耐药的试剂盒 |
| US10030272B2 (en) | 2015-02-27 | 2018-07-24 | Mayo Foundation For Medical Education And Research | Detecting gastrointestinal neoplasms |
| US10435755B2 (en) | 2015-03-27 | 2019-10-08 | Exact Sciences Development Company, Llc | Detecting esophageal disorders |
| US10689710B2 (en) * | 2015-05-27 | 2020-06-23 | Quest Diagnostics Investments Incorporated | Methods for screening solid tumors for mutations |
| US11286531B2 (en) | 2015-08-11 | 2022-03-29 | The Johns Hopkins University | Assaying ovarian cyst fluid |
| CN114574585A (zh) | 2015-08-31 | 2022-06-03 | 梅约医药教育及研究基金会 | 检测胃肿瘤 |
| RU2018123524A (ru) | 2015-12-03 | 2020-01-09 | Новартис Аг | Фармацевтическая диагностика |
| RU2608960C1 (ru) * | 2016-03-18 | 2017-01-27 | Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "РОНЦ им. Н.Н. Блохина" Минздрава России) | Клеточная линия crov Cel муцинозного рака яичников человека, предназначенная для разработки лечения таргетными препаратами |
| JP7481804B2 (ja) | 2016-04-14 | 2024-05-13 | マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ | 高度膵異形成の検出 |
| US10370726B2 (en) | 2016-04-14 | 2019-08-06 | Mayo Foundation For Medical Education And Research | Detecting colorectal neoplasia |
| JP7356349B2 (ja) | 2017-02-28 | 2023-10-04 | マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ | 前立腺癌検出 |
| JP7224645B2 (ja) * | 2017-03-30 | 2023-02-20 | 国立大学法人 東京大学 | 異なる複数の目的遺伝子の評価方法 |
| CN111868260B (zh) | 2017-08-07 | 2025-02-21 | 约翰斯霍普金斯大学 | 用于评估和治疗癌症的方法和材料 |
| JP7067896B2 (ja) | 2017-10-27 | 2022-05-16 | シスメックス株式会社 | 品質評価方法、品質評価装置、プログラム、および記録媒体 |
| JP7277460B2 (ja) | 2017-11-30 | 2023-05-19 | マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ | 乳癌の検出 |
| EP4103748A4 (en) | 2020-02-14 | 2024-03-13 | The Johns Hopkins University | METHOD AND MATERIALS FOR ASSESSING NUCLEIC ACIDS |
| CN111363827A (zh) * | 2020-04-30 | 2020-07-03 | 北京和合医学诊断技术股份有限公司 | 用于检测pik3ca基因突变的引物组及其应用方法 |
| DE102021126650A1 (de) | 2021-10-14 | 2023-04-20 | Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts | Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff |
| CN116219015A (zh) * | 2023-02-06 | 2023-06-06 | 中日友好医院(中日友好临床医学研究所) | 基于pcr的dna中pik3ca基因突变检测试剂盒及检测方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5248671A (en) * | 1989-02-15 | 1993-09-28 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6274327B1 (en) | 1992-04-13 | 2001-08-14 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
| US5846824A (en) | 1994-02-07 | 1998-12-08 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| US5846624A (en) * | 1996-12-06 | 1998-12-08 | The Standard Register Company | Dual face pressure sensitive label |
| US6277563B1 (en) | 1997-01-16 | 2001-08-21 | The Regents Of The University Of California | Genetic alterations associated with cancer |
| US7670767B1 (en) * | 1997-01-16 | 2010-03-02 | The Regents Of The University Of California | Genetic alterations associated with cancer |
| US6558903B1 (en) | 1999-06-30 | 2003-05-06 | Millennium Pharmaceuticals, Inc. | Kinases and uses thereof |
| ATE388226T1 (de) * | 1999-08-27 | 2008-03-15 | Novartis Vaccines & Diagnostic | Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon |
| WO2001055301A2 (en) * | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| WO2002027028A1 (en) * | 2000-09-28 | 2002-04-04 | Atairgin Technologies, Inc. | A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes |
| US20020142305A1 (en) | 2001-03-27 | 2002-10-03 | Koei Chin | Methods for diagnosing and monitoring ovarian cancer by screening gene copy numbers |
| US20030135033A1 (en) * | 2002-01-04 | 2003-07-17 | Anke Klippel-Giese | Compounds and methods for the identification and/ or validation of a target |
| JP2005533604A (ja) | 2002-07-25 | 2005-11-10 | アバンテック バスキュラー コーポレーション | 治療薬を送達する装置とこれに関する方法 |
| AU2004228668B2 (en) * | 2003-04-03 | 2011-10-27 | Park Funding, Llc | PI-3 kinase inhibitor prodrugs |
| JP2007530017A (ja) | 2004-03-02 | 2007-11-01 | ザ ジョンズ ホプキンス ユニバーシティ | ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 |
-
2005
- 2005-02-18 JP JP2007501815A patent/JP2007530017A/ja not_active Withdrawn
- 2005-02-18 DK DK19175606.3T patent/DK3556866T3/da active
- 2005-02-18 PT PT57232779T patent/PT1730303E/pt unknown
- 2005-02-18 PT PT17197306T patent/PT3296407T/pt unknown
- 2005-02-18 WO PCT/US2005/005193 patent/WO2005091849A2/en not_active Ceased
- 2005-02-18 PL PL17197306T patent/PL3296407T3/pl unknown
- 2005-02-18 EP EP12164819.0A patent/EP2497836B1/en not_active Expired - Lifetime
- 2005-02-18 PT PT191756063T patent/PT3556866T/pt unknown
- 2005-02-18 HU HUE17197306A patent/HUE045690T2/hu unknown
- 2005-02-18 AU AU2005227148A patent/AU2005227148B2/en not_active Expired
- 2005-02-18 CA CA2560696A patent/CA2560696C/en not_active Expired - Lifetime
- 2005-02-18 LT LTEP17197306.8T patent/LT3296407T/lt unknown
- 2005-02-18 ES ES05723277.9T patent/ES2437590T3/es not_active Expired - Lifetime
- 2005-02-18 ES ES12164819.0T patent/ES2537633T3/es not_active Expired - Lifetime
- 2005-02-18 ES ES15150891.8T patent/ES2663248T3/es not_active Expired - Lifetime
- 2005-02-18 US US10/591,347 patent/US8026053B2/en active Active
- 2005-02-18 SI SI200532262T patent/SI3296407T1/sl unknown
- 2005-02-18 DK DK17197306.8T patent/DK3296407T3/da active
- 2005-02-18 EP EP15150891.8A patent/EP2896703B1/en not_active Expired - Lifetime
- 2005-02-18 PL PL05723277T patent/PL1730303T3/pl unknown
- 2005-02-18 ES ES17197306T patent/ES2743125T3/es not_active Expired - Lifetime
- 2005-02-18 EP EP17197306.8A patent/EP3296407B1/en not_active Expired - Lifetime
- 2005-02-18 EP EP19175606.3A patent/EP3556866B1/en not_active Expired - Lifetime
- 2005-02-18 SI SI200531792T patent/SI1730303T1/sl unknown
- 2005-02-18 EP EP05723277.9A patent/EP1730303B1/en not_active Expired - Lifetime
- 2005-02-18 ES ES19175606T patent/ES2869167T3/es not_active Expired - Lifetime
- 2005-02-18 DK DK05723277.9T patent/DK1730303T3/da active
-
2011
- 2011-02-11 AU AU2011200600A patent/AU2011200600B2/en not_active Expired
- 2011-08-16 US US13/210,736 patent/US20110319477A1/en not_active Abandoned
-
2012
- 2012-03-09 JP JP2012052427A patent/JP5336620B2/ja not_active Expired - Lifetime
-
2013
- 2013-05-10 JP JP2013100073A patent/JP5894110B2/ja not_active Expired - Lifetime
-
2014
- 2014-10-31 US US14/529,351 patent/US10422006B2/en not_active Expired - Lifetime
-
2015
- 2015-12-17 JP JP2015245769A patent/JP6250017B2/ja not_active Expired - Lifetime
-
2017
- 2017-10-19 JP JP2017202265A patent/JP6395917B2/ja not_active Expired - Lifetime
- 2017-12-08 US US15/836,366 patent/US10704105B2/en not_active Expired - Lifetime
-
2018
- 2018-05-09 JP JP2018090580A patent/JP6695381B2/ja not_active Expired - Lifetime
-
2019
- 2019-08-21 CY CY20191100895T patent/CY1121975T1/el unknown
- 2019-10-07 US US16/595,055 patent/US11549150B2/en not_active Expired - Lifetime
- 2019-11-06 JP JP2019201128A patent/JP6694543B2/ja not_active Expired - Lifetime
-
2020
- 2020-03-06 JP JP2020038337A patent/JP7169315B2/ja not_active Expired - Lifetime
- 2020-04-20 US US16/853,230 patent/US10787713B2/en not_active Expired - Lifetime
- 2020-04-28 JP JP2020078786A patent/JP7001735B2/ja not_active Expired - Lifetime
-
2022
- 2022-02-17 JP JP2022022542A patent/JP7304987B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1730303E (pt) | Mutações do gene pik3ca em cancros humanos | |
| DK2456889T3 (en) | Markers of endometrial cancer | |
| JP5512935B2 (ja) | Ｒｔｋ−過剰機能−誘導障害、特に癌の治療のための阻害剤の使用 | |
| Murugan et al. | Identification and characterization of two novel oncogenic mTOR mutations | |
| KR20160068754A (ko) | 골수 악성 종양의 진단을 위한 돌연변이 칼레티쿨린 | |
| MXPA03011979A (es) | Metodos de diagnostico de cancer de ovario composiciones y metodos para rastrear moduladores de cancer de ovario. | |
| CN106459993A (zh) | Fgfr融合体 | |
| US20210062196A1 (en) | Translocation and mutant ros kinase in human non-small cell lung carcinoma | |
| PT1994410E (pt) | Métodos e estojos para detecção precoce de cancro ou de predisposição a este | |
| WO2007095038A2 (en) | Mutations and polymorphisms of erbb2 | |
| EP3309263B1 (en) | Biomarkers associated with cdk inhibitors | |
| US20100143918A1 (en) | Translocation and mutant ros kinase in human non-small cell lung carcinoma | |
| Milano et al. | Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer | |
| WO2006130527A2 (en) | Mutations and polymorphisms of fibroblast growth factor receptor 1 | |
| Simon et al. | VARIANT OF THE CHEK2GENE AS A PROGNOSTIC MARKER IN GLIOBLASTOMA MULTIFORME | |
| CN106573967A (zh) | 表皮生长因子受体基因的胞外域iii中的突变 | |
| US20040137442A1 (en) | Amplified and overexpressed gene in colorectal cancers | |
| EP2356254A1 (en) | Method for optimizing the treatment of chronic myeloid leukemia with abl tyrosine kinase inhibitors | |
| CA2773614A1 (en) | Method of treating cancer by inhibiting trim59 expression or activity | |
| CN102146441B (zh) | 一种检测急性髓系白血病易感性的试剂盒 | |
| WO2007095032A2 (en) | Mutations and polymorphisms of ptk2b | |
| WO2007002217A2 (en) | Mutations and polymorphisms of bcl-2 | |
| WO2007127524A2 (en) | Mutations and polymorphisms of insr | |
| WO2007109515A2 (en) | Mutations and polymorphisms of knockdown resistance polypeptide | |
| WO2006127609A2 (en) | Polymorphism in the macrophage migration inhibitory factor (mif) gene as marker for prostate cancer |